{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:37:10Z","timestamp":1774489030244,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T00:00:00Z","timestamp":1363824000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-136","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T03:15:04Z","timestamp":1363835704000},"source":"Crossref","is-referenced-by-count":23,"title":["Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study"],"prefix":"10.1186","volume":"13","author":[{"given":"Jun","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangjian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangqun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Jappe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Pirotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Gogov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,21]]},"reference":[{"key":"3806_CR1","first-page":"1","volume-title":"Cancer Facts and Figures 2012","author":"American Cancer Society","year":"2012","unstructured":"American Cancer Society: Cancer Facts and Figures 2012. 2012, Atlanta, GA: American Cancer Society, 1-66."},{"key":"3806_CR2","volume-title":"Globocan","author":"International Agency for Research on Cancer","year":"2008","unstructured":"International Agency for Research on Cancer: Globocan. 2008, China, [ http:\/\/globocan.iarc.fr\/factsheet.asp ], fast stats"},{"key":"3806_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1055-9965.EPI-04-0680","volume":"14","author":"L Yang","year":"2005","unstructured":"Yang L, Parkin DM, Ferlay J, Li L, Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005, 14: 243-250.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3806_CR4","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMra043172","volume":"353","author":"HT Cohen","year":"2005","unstructured":"Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med. 2005, 353: 2477-2490. 10.1056\/NEJMra043172.","journal-title":"N Engl J Med"},{"key":"3806_CR5","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, for the AVOREN Trial Investigators: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007, 370: 2103-2111. 10.1016\/S0140-6736(07)61904-7.","journal-title":"Lancet"},{"key":"3806_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, for the TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356: 125-134. 10.1056\/NEJMoa060655.","journal-title":"N Engl J Med"},{"key":"3806_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356: 115-124. 10.1056\/NEJMoa065044.","journal-title":"N Engl J Med"},{"key":"3806_CR8","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","volume":"28","author":"BI Rini","year":"2010","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010, 28: 2137-2143. 10.1200\/JCO.2009.26.5561.","journal-title":"J Clin Oncol"},{"key":"3806_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010, 28: 1061-1068. 10.1200\/JCO.2009.23.9764.","journal-title":"J Clin Oncol"},{"key":"3806_CR10","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010, 116: 4256-4265. 10.1002\/cncr.25219.","journal-title":"Cancer"},{"key":"3806_CR11","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011, 378: 1931-1939. 10.1016\/S0140-6736(11)61613-9.","journal-title":"Lancet"},{"key":"3806_CR12","unstructured":"National Comprehensive Cancer Network, Inc: The NCCN Clinical Practice Guidelines in Oncology\u2122 for Kidney Cancer V.2.2012. [ http:\/\/www.nccn.org ]"},{"key":"3806_CR13","doi-asserted-by":"publisher","first-page":"vii65","DOI":"10.1093\/annonc\/mdr034","volume":"23","author":"B Escudier","year":"2012","unstructured":"Escudier B, Kataja V: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23: vii65-vii71. 10.1093\/annonc\/mds227.","journal-title":"Ann Oncol"},{"key":"3806_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","volume":"58","author":"B Ljungberg","year":"2010","unstructured":"Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010, 58: 398-406. 10.1016\/j.eururo.2010.06.032.","journal-title":"Eur Urol"},{"key":"3806_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2008.12.010","volume":"45","author":"TM de Reijke","year":"2009","unstructured":"de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M: EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009, 45: 765-773. 10.1016\/j.ejca.2008.12.010.","journal-title":"Eur J Cancer"},{"key":"3806_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004, 4: 335-348. 10.1038\/nrc1362.","journal-title":"Nat Rev Cancer"},{"key":"3806_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1074\/jbc.270.2.815","volume":"270","author":"CJ Sabers","year":"1995","unstructured":"Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995, 270: 815-822. 10.1074\/jbc.270.2.815.","journal-title":"J Biol Chem"},{"key":"3806_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/17460441.2011.558079","volume":"6","author":"D Lebwohl","year":"2011","unstructured":"Lebwohl D, Thomas G, Lane HA, O\u2019Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi J-F, Stewart J, Motzer RJ: Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov. 2011, 6: 323-338. 10.1517\/17460441.2011.558079.","journal-title":"Expert Opin Drug Discov"},{"key":"3806_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157488411797189433","volume":"6","author":"HD Husseinzadeh","year":"2011","unstructured":"Husseinzadeh HD, Garcia JA: Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol. 2011, 6: 214-221. 10.2174\/157488411797189433.","journal-title":"Curr Clin Pharmacol"},{"key":"3806_CR20","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","volume":"26","author":"C Tanaka","year":"2008","unstructured":"Tanaka C, O\u2019Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008, 26: 1596-1602.","journal-title":"J Clin Oncol"},{"key":"3806_CR21","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008, 26: 1603-1610. 10.1200\/JCO.2007.14.5482.","journal-title":"J Clin Oncol"},{"key":"3806_CR22","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/cncr.24280","volume":"115","author":"RJ Amato","year":"2009","unstructured":"Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP: A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009, 115: 2438-2446. 10.1002\/cncr.24280.","journal-title":"Cancer"},{"key":"3806_CR23","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/jco.2007.25.18_suppl.5107","volume":"25(Suppl)","author":"J Jac","year":"2007","unstructured":"Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R: A phase II trial of RAD001 in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2007, 25(Suppl): 5107-","journal-title":"J Clin Oncol"},{"key":"3806_CR24","volume-title":"BMC Cancer","author":"A Stein","year":"2012","unstructured":"Stein A, Wang W, Carter AA, Chiparus O, Hollaender N, Kim H, Motzer RJ, Sarr C: Dynamic tumor modeling of the dose\u2013response relationship for everolimus in metastatic renal cell carcinoma using data form the phase 3 RECORD-1 trial. BMC Cancer. 2012, 12: 10.1186\/1471-2407-12-311."},{"key":"3806_CR25","volume-title":"J Clin Oncol","author":"A Stein","year":"2011","unstructured":"Stein A, Carter A, Hollaender N, Motzer R, Sarr C: Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): a dynamic tumor model of the RECORD-1 phase III trial. J Clin Oncol. 2011, 29(Suppl): abstr 4602. Presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3\u20137; Chicago, Illinois"},{"key":"3806_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-8722-4-3","volume":"4","author":"B Xu","year":"2011","unstructured":"Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R: Two dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematold Oncol. 2011, 4: 3-10.1186\/1756-8722-4-3.","journal-title":"J Hematold Oncol"},{"key":"3806_CR27","unstructured":"Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events V3.0 (CTCAE). [ http:\/\/ctep.cancer.gov ]"},{"key":"3806_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, for the RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372: 449-456. 10.1016\/S0140-6736(08)61039-9.","journal-title":"Lancet"},{"key":"3806_CR29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","volume":"47","author":"C Porta","year":"2011","unstructured":"Porta C, Ostanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ: Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011, 47: 1287-1298. 10.1016\/j.ejca.2011.02.014.","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"3806_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","volume":"16","author":"A Ravaud","year":"2011","unstructured":"Ravaud A: Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011, 16 (suppl 2): 32-44.","journal-title":"Oncologist"},{"key":"3806_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","volume":"182","author":"DA White","year":"2010","unstructured":"White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ: Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010, 182: 396-403. 10.1164\/rccm.200911-1720OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"3806_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jjco\/hyq166","volume":"41","author":"T Tsukamoto","year":"2011","unstructured":"Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H: Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol. 2011, 41: 17-24. 10.1093\/jjco\/hyq166.","journal-title":"Jpn J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-136\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T04:25:01Z","timestamp":1595564701000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,21]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3806"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-136","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,21]]},"article-number":"136"}}